Browse by author
Lookup NU author(s): Dr Salman Razvi
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Thyroid hormone levels are reduced in cardiovascular diseases and this phenomenon is associated with worse outcomes. It is unclear whether the changes in thyroid hormone bioavailability to the affected myocardium are beneficial or if this is a maladaptive response. Experimental studies from animal models of acute myocardial infarction (AMI) suggest that thyroid hormone treatment may be beneficial. There is limited data available on the use of thyroid hormones in patients with AMI and heart failure and this suggests that treatment to normalise thyroid hormone levels may be safe and potentially effiicacious. Similarly, evidence of thyroid hormone therapy in patients undergoing cardiac surgery or during cardiac transplantation is limited. It is therefore diffiicult to draw any fi rm conclusions about benefits or risks of thyroid hormone treatment in these conditions. Large scale clinical trials of thyroid hormones in patients with cardiac conditions are required to confi rm safety and evaluate effi cacy. Furthermore, it needs to be elucidated which hormone to administer (thyroxine or triiodothyronine), when in the disease pathway to treat, dose of thyroid hormone to administer, and which parameters to utilise to assess safety and effi cacy. Until these important questions are answered thyroid hormone therapy in cardiovascular diseases must remain within the research domain.
Author(s): Razvi S
Publication type: Review
Publication status: Published
Journal: Endocrine
Year: 2019
Volume: 66
Issue: 1
Pages: 115–123
Online publication date: 15/10/2019
Acceptance date: 05/08/2019
ISSN (print): 1355-008X
ISSN (electronic): 1559-0100
URL: https://doi.org/10.1007/s12020-019-02050-4
DOI: 10.1007/s12020-019-02050-4
